查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1867274

阿片类药物市场按阿片类药物类型、给药途径、用途和最终用户划分－2025年至2032年全球预测

Opioids Market by Opioid Types, Mode of Administration, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，阿片类药物市场规模将成长至 299.6 亿美元，年复合成长率为 4.21%。

关键市场统计数据
基准年 2024 215.3亿美元
预计年份：2025年 224.4亿美元
预测年份 2032 299.6亿美元
复合年增长率 (%) 4.21%

对阿片类药物治疗现况的简要概述，阐述临床需求、监管压力和决策者的策略重点。

在治疗需求、安全问题和不断演变的法规结构交织的复杂背景下，阿片类药物治疗领域持续受到临床、监管和政策相关人员的密切关注。本导言阐述了本报告所采用的分析观点，将鸦片类药物置于现代治疗路径中，同时强调需要在有效缓解疼痛和麻醉的同时，加强对滥用和不良后果的防范。透过整合临床实务趋势、监管发展和供应链现状，本报告重点阐述了药物研发人员、医疗保健提供者和公共卫生组织面临的关键挑战和机会。

不断发展的临床实践、法律规范和剂量创新如何重塑医疗保健机构中阿片类药物治疗的开发和管理

阿片类药物治疗领域正经历变革性的转变，临床实务、产品研发和监管都在重塑。合成鸦片类药物化学的进步，加上监管力度的加强和处方控制的日益严格，正在推动控释剂型的重新研发和滥用抑制技术的探索。同时，给药系统的创新，例如改良的经皮基质和定向注射製剂，正在重新定义各种医疗机构中镇痛和麻醉的给药方式。

评估2025年贸易关税调整对阿片类药物供应链、采购经济及临床取得策略的累积影响

2025年美国关税对鸦片类药物供应链产生了累积影响，波及原料采购、生产物流和临床采购等各环节。某些前驱物和成品药进口关税的提高，迫使製造商重新审视投入成本，并重新评估其供应商组合和合约条款。为此，许多相关人员加快了多元化策略的实施，优先考虑本地采购，并对替代供应商进行资格审核，以降低关税带来的成本上行风险。

透过多维細項分析，突显治疗类别、给药途径、临床应用和最终用户部署的影响，可以帮助制定策略。

精细化的细分框架能够辨识治疗研发和临床应用的分歧与融合领域，为策略优先排序提供切实可行的观点。以鸦片类药物类型进行分析，突显了天然鸦片类药物（如可待因和氢可酮）、半合成药物（如氢可酮和羟考酮）以及全合成化合物（包括Fentanyl和美沙酮）之间的差异。每类药物都具有独特的药理学特性、监管控制和临床应用案例，这些都会影响製剂和监测要求。

管理体制、医疗保健基础设施和支付方优先事项的区域差异如何影响阿片类药物产品开发和取得的不同策略。

区域趋势正在影响临床实践和商业性路径，由此产生的显着差异会影响优先事项的製定和执行。在美洲，临床指引和支付方框架强调药物管理，同时确保在急性照护环境中持续获得必要的止痛药物。这使得风险缓解策略和真实世界证据的收集显得尤为重要。同时，在欧洲、中东和非洲，监管差异和不同的报销模式导致新製剂和滥用预防技术的推广应用曲线存在差异，因此需要针对不同区域制定市场准入和监管策略。

公司层面的策略性因应措施反映了优先事项的趋同：安全创新、一体化生产以及为维持临床准入而产生的证据。

阿片类药物治疗生态系统中的主要企业正在展现出多样化的策略性应对措施，这些措施可为竞争对手和合作伙伴提供宝贵的经验。业界领导企业正在投资製剂技术，以降低滥用风险并加强安全监测，同时扩大其无菌生产和受管制物质分销能力。一些公司正与医疗设备製造商合作，将药理特性与给药方案结合，以提高剂量准确性和患者依从性。

领导者应专注于以安全为中心的创新、供应链韧性和协作管理，以保障准入和价值，并制定切实可行的策略重点。

产业领导者应采取一系列切实可行的措施，将洞察转化为可捍卫的优势，同时确保病患安全和符合监管要求。首先，应优先开发和推广具有防滥用和安全性增强功能的製剂，并建立健全的药物监测系统，及时产生真实世界证据，以支持临床和支付者之间的对话。其次，应投资加强供应链韧性，透过供应商多元化、策略性库存缓衝以及对区域生产合作伙伴进行合格，降低贸易和关税波动带来的风险。

本分析所依据的研究方法采用了一种严谨的混合方法，结合了证据综合、相关人员访谈和情境分析，以得出有充分理由的策略结论和建议。

本分析的调查方法结合了对同侪审查的临床文献、监管申报文件和公共文件的系统性回顾，以及对临床、生产和监管相关人员的结构化访谈。资料收集优先考虑记录治疗效果、安全性概况和政策变化的资讯来源，而综合分析则强调跨不同证据来源的三角验证，以增强推论的有效性。定性访谈旨在收集有关供应链、製剂挑战和实施障碍的实际观点，从而将策略主题与实际情况联繫起来。

临床安全、商业性韧性和协作管治这三者相互交织的迫切需求，对于维持阿片类药物的可及性和创新至关重要。

总之，阿片类药物治疗领域正处于转折点，需要各方共同努力，推动安全创新、增强供应链稳健性并加强跨部门合作。製剂科学和给药技术的变革为改善治疗效果提供了契机，而监管和贸易趋势也带来了新的限制因素，需要製定适应性强的商业和营运策略。透过将实证实践与药物管理计画和健全的采购惯例结合，相关人员可以在保障临床用药的同时，推动公共卫生目标的实现。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 远端医疗辅助药物治疗鸦片类药物使用障碍的激增
  • 广泛采用人工智慧驱动的处方药物监测计划，以防止处方药滥用
  • 突破性专利到期加速非专利鸦片类止痛药上市
  • 利用新型聚合物基质技术，扩大耐滥用配方的应用范围
  • 透过州处方药处方笺扩大社区药局纳洛酮的分发范围
  • 加强支付方与医疗服务提供方在基于价值的阿片类药物治疗合约方面的合作
  • 加强对Fentanyl和Fentanyl等非法合成鸦片类药物类似物的监管审查
  • 过渡到其他非鸦片类镇痛疗法，包括 CGRP 和 TRPV1 抑制剂
  • 加强真实世界证据研究，以证明药物辅助治疗方案的成本效益
  • 关于阿片类药物诉讼和解及资金分配透明度的新法律挑战

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按阿片类药物类型分類的阿片类药物市场

  • 天然鸦片
    • 可待因
    • 氢可酮
  • 半合成鸦片类药物
    • 氢可酮
    • 羟考酮
  • 合成鸦片类药物
    • Fentanyl
    • 美沙酮

9. 依给药途径分類的鸦片类药物市场

  • 口服
    • 胶囊
    • 药片
  • 肠外给药
    • 肌肉内注射
    • 静脉注射
  • 经皮给药

第十章 阿片类药物市场依应用领域划分

  • 麻醉
    • 全身麻醉
    • 局部麻醉
  • 抑制咳嗽
  • 疼痛管理
    • 急性疼痛
    • 慢性疼痛

第十一章 以最终用户分類的鸦片类药物市场

  • 医疗机构
    • 诊所
    • 医院
  • 家庭医疗保健
  • 研究所

第十二章：各地区的鸦片类药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：按类别分類的鸦片类药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国阿片类药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Alvogen
    • Apotex Inc.
    • Biesterfeld SE
    • Daiichi Sankyo Company, Limited
    • Elite Pharmaceuticals, Inc.
    • Endo International plc
    • Fresenius SE & Co. KGaA
    • Humanwell Healthcare（Group）Co., Ltd.
    • Indivior PLC
    • Johnson & Johnson Services, Inc.
    • Johnson Matthey Group
    • Kyowa Hakko Kirin Co. Ltd.
    • Mallinckrodt plc
    • Nutriband Inc.
    • Piramal Pharma Limited
    • Purdue Pharma LP
    • QuVa Pharma, Inc
    • SCA Pharma
    • Spectrum Chemical Mfg. Corp.
    • Teva Pharmaceutical Industries Ltd.
    • Tofigh Daru Research & Engineering Company
    • Verve HumanCare Laboratories
    • Viatris Inc.
Product Code: MRR-CB04E05659AC

The Opioids Market is projected to grow by USD 29.96 billion at a CAGR of 4.21% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.53 billion
Estimated Year [2025] USD 22.44 billion
Forecast Year [2032] USD 29.96 billion
CAGR (%) 4.21%

A concise orientation to the opioid therapeutics landscape framing clinical imperatives, regulatory pressure, and strategic priorities for decision-makers

The opioid therapeutics landscape continues to prompt intense scrutiny from clinical, regulatory, and policy stakeholders, driven by complex intersections of therapeutic necessity, safety concerns, and evolving regulatory frameworks. This introduction sets out the analytical lens used in the report, situating opioids within contemporary care pathways while recognizing the imperative to balance effective analgesia and anesthesia against heightened vigilance for misuse and adverse outcomes. By synthesizing clinical practice trends, regulatory signals, and supply chain realities, the report frames the primary challenges and opportunities facing pharmaceutical developers, healthcare providers, and public health agencies.

Throughout this analysis, emphasis is placed on evidence-based evaluation of therapeutic classes, routes of administration, clinical applications, and end-user dynamics. The intent is to provide decision-makers with a clear, structured understanding of where clinical demand intersects with regulatory pressures and innovation trajectories. With that orientation established, subsequent sections explore transformative shifts, policy impacts, segmentation insights, and regional dynamics, all designed to inform strategic planning, clinical protocol development, and investment prioritization.

How evolving clinical practice, regulatory oversight, and delivery innovation are reshaping opioid therapy development and stewardship across care settings

The landscape of opioid therapeutics is in the midst of transformative shifts that recalibrate clinical practice, product development, and regulatory oversight. Advances in synthetic opioid chemistry, coupled with intensified monitoring and prescription controls, have encouraged the redevelopment of controlled formulations and the exploration of abuse-deterrent technologies. At the same time, innovation in delivery systems, such as refined transdermal matrices and targeted parenteral formulations, is redefining how analgesia and anesthesia are administered across care settings.

Concurrently, payer and provider policies are shifting toward evidence-based protocols that emphasize multimodal pain management and stewardship programs designed to minimize long-term opioid exposure. These trends are accelerating the adoption of alternative pain pathways and driving more rigorous post-marketing surveillance, thereby increasing the bar for new product entry and lifecycle management. As a result, developers and clinical leaders must adapt to an environment that rewards demonstrable safety improvements, real-world outcomes data, and collaborative approaches that integrate pharmacy, surgery, and primary care perspectives.

Assessing the cumulative ramifications of 2025 trade tariff adjustments on opioid supply chains, procurement economics, and clinical access strategies

The United States tariff measures implemented in 2025 exerted a cumulative influence across the opioid supply chain, reverberating through raw material sourcing, manufacturing logistics, and clinical procurement. Increased import levies on certain precursors and finished formulations elevated input cost considerations for manufacturers, prompting reassessments of supplier portfolios and contractual terms. In response, many stakeholders accelerated diversification strategies that prioritized regional sourcing and qualified alternate suppliers to mitigate exposure to tariff-driven costs.

These trade policy shifts also affected distribution economics and inventory strategies for hospitals, clinics, and home healthcare providers, who faced amplified scrutiny of procurement spend and inventory turn. In turn, manufacturers and distributors revisited pricing, contractual rebates, and rebate timing to preserve access while managing margin pressure. Importantly, regulatory authorities and industry associations emphasized compliance and transparency around cost pass-through to ensure continued patient access to critical therapies. The net effect underscores a heightened need for resilient supply chain design, proactive regulatory engagement, and commercial agility to navigate evolving trade and tariff environments without compromising clinical continuity.

A multi-dimensional segmentation analysis clarifying therapeutic categories, delivery pathways, clinical applications, and end-user deployment implications for strategy

A nuanced segmentation framework reveals where therapeutic development and clinical deployment diverge and converge, providing practical lenses for strategic prioritization. When parsed by opioid types, distinctions emerge between natural opiates such as codeine and morphine, semi-synthetic agents exemplified by hydrocodone and oxycodone, and fully synthetic compounds including fentanyl and methadone, each category carrying distinct pharmacology, regulatory controls, and clinical use cases that influence formulation and monitoring requirements.

Equally informative is segmentation by mode of administration, which contrasts oral routes-implemented in capsules and tablets-with parenteral options that require intramuscular or intravenous delivery, and with transdermal systems designed for sustained release. These administration pathways create divergent requirements for dosing accuracy, abuse deterrence, and device compatibility. Application-focused segmentation differentiates anesthesia applications, both general and regional, from indications like cough suppression and pain management, where acute and chronic pain profiles demand tailored therapeutic strategies and monitoring. Finally, end-user segmentation highlights deployment environments spanning healthcare facilities, where clinics and hospitals each present different formularies and utilization patterns, home healthcare settings that prioritize portability and safety, and research institutes that drive clinical innovation and early-stage evaluation. Together, these segmentation lenses support targeted product development, differentiated commercial strategies, and informed clinical policy design.

How divergent regulatory regimes, healthcare infrastructures, and payer priorities across global regions shape tailored strategies for opioid product development and access

Regional dynamics shape both clinical practice and commercial pathways, with discernible differences that affect prioritization and execution. In the Americas, clinical guidelines and payer frameworks emphasize stewardship while enabling continued access to essential analgesics across acute care settings; this creates a climate where risk mitigation strategies and real-world evidence collection are particularly salient. Meanwhile, in Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement models create differentiated adoption curves for new formulations and abuse-deterrent technologies, necessitating tailored market-entry and regulatory strategies.

Across Asia-Pacific, rapid modernization of healthcare infrastructure and expanding clinical research capacity have catalyzed interest in novel delivery systems and localized manufacturing partnerships. The synthesis of these regional patterns suggests that successful strategies will blend global evidence generation with region-specific regulatory engagement and supply chain redundancy. Moreover, cross-regional learning, where best practices in stewardship and device integration migrate between geographies, will further influence how therapies are adopted and optimized at the point of care.

Company-level strategic responses reveal converging priorities on safety innovation, integrated manufacturing, and evidence generation to sustain clinical access

Key companies within the opioid therapeutics ecosystem demonstrate varied strategic responses that offer instructive lessons for competitors and collaborators. Industry leaders are investing in formulation technologies that reduce abuse potential and improve safety monitoring while simultaneously expanding capabilities in sterile manufacturing and controlled-substance logistics. A subset of organizations is pursuing partnerships with device manufacturers to couple pharmacology with delivery solutions that enhance dosing precision and patient adherence.

In parallel, several established firms are reallocating resources toward post-market evidence generation and pharmacovigilance systems to support regulatory filings and payer negotiations. Smaller, innovation-focused companies commonly concentrate on niche clinical applications or novel chemical entities that address unmet needs in anesthesia or chronic pain, while contract development and manufacturing organizations serve as critical enablers by providing specialized capabilities for controlled-substance production. Collectively, these company-level strategies underscore the primacy of safety innovation, regulatory collaboration, and integrated supply chain competencies.

Practical strategic priorities for leaders focused on safety-driven innovation, supply chain resilience, and collaborative stewardship to protect access and value

Industry leaders must adopt a set of actionable steps that translate insights into defensible advantage while maintaining patient safety and regulatory compliance. First, prioritize development and deployment of abuse-deterrent and safety-enhanced formulations alongside robust pharmacovigilance frameworks that generate timely real-world evidence to support clinical and payer dialogues. Second, invest in supply chain resilience through supplier diversification, strategic stock buffering, and qualification of regional manufacturing partners to reduce exposure to trade and tariff volatility.

Third, coordinate cross-functional engagement among clinical leaders, formulary committees, and payer representatives to design stewardship programs that align clinical outcomes with responsible prescribing. Fourth, pursue technology partnerships that integrate drug-device combinations and digital adherence tools to differentiate therapeutic offerings and improve patient monitoring. Finally, maintain proactive regulatory engagement and transparent communication with public health stakeholders to accelerate approvals and sustain access while demonstrating commitment to mitigating misuse and adverse outcomes. These combined actions will strengthen competitive positioning and uphold clinical responsibility.

A rigorous mixed-methods approach combining evidence synthesis, stakeholder interviews, and scenario analysis to produce defensible strategic conclusions and recommendations

The research methodology underpinning this analysis integrates systematic review of peer-reviewed clinical literature, regulatory filings, and public policy documents with structured interviews conducted across clinical, manufacturing, and regulatory stakeholders. Data collection prioritized sources that document therapeutic performance, safety profiles, and policy shifts, and synthesis emphasized triangulation among diverse evidence streams to strengthen inference validity. Qualitative interviews were designed to capture operational perspectives on supply chains, formulation challenges, and adoption barriers, enabling the report to connect strategic themes with on-the-ground realities.

Analytical approaches included thematic coding of stakeholder interviews, comparative assessment of regulatory frameworks, and scenario-based evaluation of trade and procurement impacts. Throughout, the methodology emphasized transparency in source attribution and reproducibility in analytic steps, allowing practitioners to trace conclusions back to primary evidence. Where appropriate, sensitivity analyses were conducted to test robustness of narrative conclusions against alternative policy or supply chain scenarios, ensuring that recommendations remain actionable across plausible futures.

Converging imperatives for clinical safety, commercial resilience, and collaborative stewardship to sustain access and innovation in opioid therapeutics

In conclusion, the opioid therapeutics sector is at an inflection point that demands concerted attention to safety innovation, supply chain robustness, and cross-sector collaboration. Transformations in formulation science and delivery technologies present opportunities to improve therapeutic outcomes while regulatory and trade developments impose new constraints that require adaptive commercial and operational strategies. By integrating evidence generation with stewardship programs and resilient sourcing practices, stakeholders can preserve clinical access while advancing public health objectives.

Moving forward, success will depend on organizations that align product development with demonstrable safety advantages, cultivate regional manufacturing and distribution flexibility, and invest in partnerships that enhance monitoring and adherence. The recommendations presented herein offer a pathway to reconcile clinical necessity with societal expectations, enabling responsible stewardship and sustained access to essential therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in telemedicine-based medication-assisted treatment for opioid use disorder
  • 5.2. Widespread integration of AI-driven prescription drug monitoring programs to prevent misuse
  • 5.3. Accelerated launch of generic opioid analgesics following landmark patent expirations
  • 5.4. Growing adoption of abuse-deterrent formulations with novel polymer matrix technologies
  • 5.5. Expansion of community pharmacy naloxone distribution through state standing orders
  • 5.6. Rising collaborations between payers and providers on value-based opioid treatment contracts
  • 5.7. Intensified regulatory scrutiny on illicit synthetic opioid analogues like fentanyl and carfentanil
  • 5.8. Shift towards non-opioid pain management alternatives including CGRP and TRPV1 inhibitors
  • 5.9. Enhanced real-world evidence studies demonstrating cost effectiveness of MOUD programs
  • 5.10. Emerging legal challenges around opioid litigation settlements and fund allocation transparency

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Opioids Market, by Opioid Types

  • 8.1. Natural Opiates
    • 8.1.1. Codeine
    • 8.1.2. Morphine
  • 8.2. Semi-Synthetic Opioids
    • 8.2.1. Hydrocodone
    • 8.2.2. Oxycodone
  • 8.3. Synthetic Opioids
    • 8.3.1. Fentanyl
    • 8.3.2. Methadone

9. Opioids Market, by Mode of Administration

  • 9.1. Oral Administration
    • 9.1.1. Capsules
    • 9.1.2. Tablets
  • 9.2. Parenteral Administration
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
  • 9.3. Transdermal Administration

10. Opioids Market, by Application

  • 10.1. Anesthesia
    • 10.1.1. General Anesthesia
    • 10.1.2. Regional Anesthesia
  • 10.2. Cough Suppression
  • 10.3. Pain Management
    • 10.3.1. Acute Pain
    • 10.3.2. Chronic Pain

11. Opioids Market, by End-User

  • 11.1. Healthcare Facilities
    • 11.1.1. Clinics
    • 11.1.2. Hospitals
  • 11.2. Home Healthcare
  • 11.3. Research Institutes

12. Opioids Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Opioids Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Opioids Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Hikma Pharmaceuticals PLC
    • 15.3.2. Pfizer Inc.
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Alvogen
    • 15.3.5. Apotex Inc.
    • 15.3.6. Biesterfeld SE
    • 15.3.7. Daiichi Sankyo Company, Limited
    • 15.3.8. Elite Pharmaceuticals, Inc.
    • 15.3.9. Endo International plc
    • 15.3.10. Fresenius SE & Co. KGaA
    • 15.3.11. Humanwell Healthcare (Group) Co., Ltd.
    • 15.3.12. Indivior PLC
    • 15.3.13. Johnson & Johnson Services, Inc.
    • 15.3.14. Johnson Matthey Group
    • 15.3.15. Kyowa Hakko Kirin Co. Ltd.
    • 15.3.16. Mallinckrodt plc
    • 15.3.17. Nutriband Inc.
    • 15.3.18. Piramal Pharma Limited
    • 15.3.19. Purdue Pharma L.P.
    • 15.3.20. QuVa Pharma, Inc
    • 15.3.21. SCA Pharma
    • 15.3.22. Spectrum Chemical Mfg. Corp.
    • 15.3.23. Teva Pharmaceutical Industries Ltd.
    • 15.3.24. Tofigh Daru Research & Engineering Company
    • 15.3.25. Verve HumanCare Laboratories
    • 15.3.26. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPIOIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. OPIOIDS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. OPIOIDS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPIOIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPIOIDS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPIOIDS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPIOIDS MARKET SIZE, BY NATURAL OPIATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPIOIDS MARKET SIZE, BY CODEINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPIOIDS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPIOIDS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPIOIDS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPIOIDS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPIOIDS MARKET SIZE, BY METHADONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPIOIDS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPIOIDS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPIOIDS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPIOIDS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPIOIDS MARKET SIZE, BY TRANSDERMAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPIOIDS MARKET SIZE, BY ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OPIOIDS MARKET SIZE, BY GENERAL ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OPIOIDS MARKET SIZE, BY REGIONAL ANESTHESIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OPIOIDS MARKET SIZE, BY COUGH SUPPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OPIOIDS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OPIOIDS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OPIOIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OPIOIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OPIOIDS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL OPIOIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS OPIOIDS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 333. MIDDLE EAST OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 334. MIDDLE EAST OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 335. MIDDLE EAST OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 336. MIDDLE EAST OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 337. MIDDLE EAST OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 338. MIDDLE EAST OPIOIDS MARKET SIZE, BY SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 339. MIDDLE EAST OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. MIDDLE EAST OPIOIDS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. MIDDLE EAST OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. MIDDLE EAST OPIOIDS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. MIDDLE EAST OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 344. MIDDLE EAST OPIOIDS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 345. MIDDLE EAST OPIOIDS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. MIDDLE EAST OPIOIDS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. MIDDLE EAST OPIOIDS MARKET SIZE, BY ANESTHESIA, 2018-2024 (USD MILLION)
  • TABLE 348. MIDDLE EAST OPIOIDS MARKET SIZE, BY ANESTHESIA, 2025-2032 (USD MILLION)
  • TABLE 349. MIDDLE EAST OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 350. MIDDLE EAST OPIOIDS MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 351. MIDDLE EAST OPIOIDS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 352. MIDDLE EAST OPIOIDS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 353. MIDDLE EAST OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2018-2024 (USD MILLION)
  • TABLE 354. MIDDLE EAST OPIOIDS MARKET SIZE, BY HEALTHCARE FACILITIES, 2025-2032 (USD MILLION)
  • TABLE 355. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. AFRICA OPIOIDS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2018-2024 (USD MILLION)
  • TABLE 358. AFRICA OPIOIDS MARKET SIZE, BY OPIOID TYPES, 2025-2032 (USD MILLION)
  • TABLE 359. AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2018-2024 (USD MILLION)
  • TABLE 360. AFRICA OPIOIDS MARKET SIZE, BY NATURAL OPIATES, 2025-2032 (USD MILLION)
  • TABLE 361. AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 362. AFRICA OPIOIDS MARKET SIZE, BY SEMI-SYNTHETIC OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 363. AFRICA OPIOIDS MARKET S